Synendos Therapeutics, has received approval from the European Medicines Agency (EMA) to commence the Phase I first-in-human clinical trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the endocannabinoid system (ECS) to restore healthy brain physiology. The randomised, double-blind, placebo-controlled study will investigate the safety, tolerability and […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!